Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 5/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520393 | 0.97 | TSHR (0.48) | TSHRALOX15HSD17B10SOAT1GRIN2B | |
| SCHEMBL14520340 | 0.90 | SOAT1 (0.55) | TSHRSOAT1ALDH1A1JAK2SMN1; SMN2 | |
| SCHEMBL14520390 | 0.86 | SOAT1 (0.52) | TSHRSOAT1ALDH1A1SMN1; SMN2RAB9A | |
| Hydrochloric Acid SCHEMBL5492877 | 0.85 | GRIN2B (0.51) | TSHRGRIN2BALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL4878061 | 0.81 | SOAT1 (0.58) | SOAT1MAPT | |
| SCHEMBL14520332 | 0.81 | SOAT1 (0.56) | TSHRALOX15HSD17B10SOAT1 | |
| SCHEMBL14520343 | 0.80 | SOAT1 (0.57) | SOAT1 | |
| SCHEMBL4873768 | 0.80 | SOAT1 (0.55) | TSHRSOAT1ALDH1A1MAPT | |
| SCHEMBL4880670 | 0.79 | SOAT1 (0.54) | SOAT1 | |
| SCHEMBL4876634 | 0.79 | SOAT1 (0.52) | SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-20070078120-A1 | Novel piperidine derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078120-A1 | Novel piperidine derivative | LDLR, PRMT5, MSR1 | TSHR 836/4885ALOX15 3921/4885HSD17B10 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.